May 4 (Reuters) – Takeda Pharmaceutical said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage clinical trial.
(Reporting by Sahil Pandey in Bengaluru; Editing by Shilpi Majumdar)
Comments